As such, targeting neuraminidases, particularly NEU1, NEU2, and NEU3, may offer novel therapeutic strategies for obesity, type 2 diabetes, and NAFLD. Here, NEU1 is linked to obesity due to melanocortin 4 receptor deficiency.